Sort
48,018 grants matching “immunotherapy”
NR4A1 Antagonists Inhibit Colorectal Cancer Growth and Enhance Immune Surveillance
$571,380Stephen H Safe · Texas A&M University · R01 · FY2025 · CA
Adoptive MHC-E-Restricted T Cell Therapy for the Treatment of Chronic Hepatitis B Virus Infection
$571,249Benjamin J Burwitz · Oregon Health & Science University · R01 · FY2022 · AI
Role of IRF2 in cancer immune evasion and immunotherapy
$571,214Kenneth L Rock · Univ Of Massachusetts Med Sch Worcester · R01 · FY2022 · CA
Role of IRF2 in cancer immune evasion and immunotherapy
$571,214Kenneth L Rock · Univ Of Massachusetts Med Sch Worcester · R01 · FY2023 · CA
Development of Novel Spontaneous HPV Cervicovaginal Carcinoma Models for Cancer Immunotherapy
$571,193T.-C. Wu · Johns Hopkins University · R01 · FY2022 · CA
Correction of diabetic retinopathy by mitochondrial transfer
$571,182Denis A Proshlyakov · Michigan State University · R01 · FY2023 · EY
Overcoming Immunotherapy Resistance Through Opioid Antagonism in Head and Neck Cancer
$571,177Nicole N Scheff · University Of Pittsburgh At Pittsburgh · R01 · FY2025 · DE
Dendritic Cell mediated induction of Anti-HCV immunity
$571,176Nina Bhardwaj · New York University School Of Medicine · R01 · FY2008 · AI
USE OF TEG TO MONITOR GPIIB/IIIA AT THE BEDSIDE
$571,150Haemoscope Corporation · R44 · FY2000 · HL
Phase II Clinical Development of Galectin-3 Inhibition and Anti-PD-1: Immune Monitoring and Tumor Response
$571,136Brendan D Curti · Providence Portland Medical Center · R01 · FY2024 · CA
SUMOylation disruption is toxic for SS18-SSX-driven synovial sarcoma
$571,084Anthony Charles Faber · Virginia Commonwealth University · R01 · FY2023 · CA
Overcoming hypoxic resistance to anti-cancer therapy
$571,062Nicholas C Denko · Ohio State University · R01 · FY2022 · CA
Overcoming hypoxic resistance to anti-cancer therapy
$571,062Nicholas C Denko · Ohio State University · R01 · FY2023 · CA
Improving anti-tumor T cell immunity by targeting LDH-A functions beyond the Warburg effect
$571,003Vassiliki A Boussiotis · Beth Israel Deaconess Medical Center · R01 · FY2020 · CA
Improving anti-tumor T cell immunity by targeting LDH-A functions beyond the Warburg effect
$571,003Vassiliki A Boussiotis · Beth Israel Deaconess Medical Center · R01 · FY2021 · CA
Identifying and targeting neoantigens in aggressive salivary carcinomas
$570,903Luc Gordon Trang Morris · Sloan-Kettering Inst Can Research · R01 · FY2018 · DE
Dual action immunostimulatory nanoparticles for treatment of aggressive cancers
$570,868Efstathios Karathanasis · Case Western Reserve University · R01 · FY2024 · CA
Development of Novel Spontaneous HPV Cervicovaginal Carcinoma Models for Cancer Immunotherapy
$570,782T.-C. Wu · Johns Hopkins University · R01 · FY2023 · CA
Phase I therapeutic testing of viral-vectored vaccines that shift CD8+ T cell immunodominance to conserved regions of HIV-1
$570,647Nilu Goonetilleke · Univ Of North Carolina Chapel Hill · U01 · FY2023 · AI
Transcriptional heterogeneity and regulatory mechanisms in tumor microenvironment
$570,593Sridhar Hannenhalli · Division Of Basic Sciences - Nci · ZIA · FY2024 · CA
Regulatory T Cells and Pulmonary Hypertension
$570,589Mark Robert Nicolls · Palo Alto Veterans Instit For Research · R01 · FY2024 · HL
Translational Combinations of Nanocarriers and Blockers for Metastatic Breast Cancer
$570,553Andrew Michael Smith · University Of Illinois At Urbana-Champaign · R01 · FY2025 · CA
Translational Combinations of Nanocarriers and Blockers for Metastatic Breast Cancer
$570,553Andrew Michael Smith · University Of Illinois At Urbana-Champaign · R01 · FY2024 · CA
Improving Glioma Immunotherapy Efficacy by Regulating Tumor Inflammation
$570,541Behnam Badie · Beckman Research Institute/City Of Hope · R01 · FY2024 · NS
Single Cell Genome-Wide Myeloid Response Profiling in Immunotherapy
$570,518Allon Moshe Klein · Harvard Medical School · R01 · FY2018 · CA